Cover Image

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV

Saved in:
Bibliographic Details
Other Authors: Hehlmann, Rüdiger (Other) , Müller, Martin Christian (Other) , Hanfstein, Benjamin (Other) , Fabarius, Alice (Other) , Schreiber, Annette (Other) , Proetel, Ulrike (Other) , Dengler, Jolanta (Other) , Saußele, Susanne (Other)
Format: Article (Journal)
Language:English
Published: 2014
In: Journal of clinical oncology
Year: 2014, Volume: 32, Issue: 5, Pages: 415-423
ISSN:1527-7755
DOI:10.1200/JCO.2013.49.9020
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1200/JCO.2013.49.9020
Get full text
Author Notes:Hehlmann, Rüdiger; Müller, Martin C.; Lauseker, Michael; Hanfstein, Benjamin; Fabarius, Alice; Schreiber, Annette; Proetel, Ulrike; Pletsch, Nadine; Pfirrmann, Markus; Haferlach, Claudia; Schnittger, Susanne; Einsele, Hermann; Dengler, Jolanta; Falge, Christiane; Kanz, Lothar; Neubauer, Andreas; Kneba, Michael; Stegelmann, Frank; Pfreundschuh, Michael; Waller, Cornelius F.; Spiekermann, Karsten; Bärlocher, Gabriela M.; Ehninger, Gerhard; Heim, Dominik; Heimpel, Hermann; Nerl, Christoph; Krause, Stefan W.; Hossfeld, Dieter K.; Kolb, Hans-Jochem; Hasford, Jörg; Saussele, Susanne; Hochhaus, Andreas
Description
Item Description:Gesehen am 23.06.2015
Physical Description:Online Resource
ISSN:1527-7755
DOI:10.1200/JCO.2013.49.9020

Similar Items